Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Proceedings of the National Academy of Sciences of the United States of America|February 18, 2010
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsMichael A Curran, Welby Montalvo, Hideo Yagita, et al.Proceedings of the National Academy of Sciences of the United States of America|December 22, 2010
Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenanceVirginia A Pedicord, Welby Montalvo, Ingrid M Leiner, et al.Cancer Immunology Research|July 20, 2014
Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motilityTsvetelina Pentcheva-Hoang, Tyler R Simpson, Welby Montalvo-Ortiz, et al.Plos One|May 12, 2011
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine productionMichael A Curran, Myoungjoo Kim, Welby Montalvo, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 28, 2015
Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readinessVirginia A Pedicord, Justin R Cross, Welby Montalvo-Ortiz, et al.The Journal of Experimental Medicine|April 3, 2013
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of EomesoderminMichael A Curran, Theresa L Geiger, Welby Montalvo, et al.Science Immunology|April 10, 2021
Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responsesJoyce Wei, Welby Montalvo-Ortiz, Lola Yu, et al.The Journal of Experimental Medicine|July 31, 2013
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaTyler R Simpson, Fubin Li, Welby Montalvo-Ortiz, et al.Glycobiology|June 21, 2023
VSIG4 interaction with heparan sulfates inhibits VSIG4-complement bindingSarah Y Ebstein, Ashique Rafique, Yi Zhou, et al.Science Translational Medicine|November 9, 2022
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma modelsJoyce Wei, Welby Montalvo-Ortiz, Lola Yu, et al.Pageof 1